Endogena Therapeutics, Inc.’s Post

Mark Kotter shares his insights on the translation gap in drug development and the importance of using human cells from the onset to overcome the challenges of treating human diseases 🚀💡 #TranslationGap #StemCellBiology #TheBiotechStartupsPodcast

I am looking forward to joining Wen Zhang, MD PhD tomorrow for a discussion on IgG4-RD treatments and updates on trials for new steroid-sparing alternatives. The current standard treatment around the world for #IgG4RD is glucocorticoids. But is the role of steroids in treating this disease outsized? Join us for more on this insightful topic: https://hubs.li/Q028G0tD0 #SteroidToxicity #Rheumatology #Vasculitis

How peptides and oligonucleotides are a different class of compounds, how they are changing the way diseases are being treated, and the complex methodologies involved in producing them. #peptides #oligonucleotides #biopharma #CQAs #Drugs Watch: https://lnkd.in/gvhSczbS

https://lnkd.in/gupRRiJk It took an act of Congress in 1991 for Agent Orange effects to be recognized as a serious medical problem (types of cancer, diabetes, birth defects) to be treated by the VA, other medical facilities & doctors. Over 300,000 Vietnam vets have died from Agent Orange illnesses (over 400,000 Vietnamese) besides the over 58,000 combat deaths. So many of the remaining several hundred thousand Vietnam Vets have cancer. At least Congress too action on Burn Pitt related illnesses. 

Save the dates! We will be presenting: Acute Ischemic Hepatitis due to Portal Vein Thrombosis Post Roux-en-Y Gastric Bypass: A Case Report

Best diagnostic solution for thrombosis and haemostasis ever!

The PORTOLA Trial is evaluating zetomipzomib, a first-in-class agent for the treatment of autoimmune hepatitis. To learn more visit https://lnkd.in/gmfuvjhH #PORTOLAtrial #zetomipzomib

Spotlight on Retinitis Pigmentosa 👁️🗨️ Today, we’re highlighting how individuals with retinitis pigmentosa (RP) may experience the progression of their vision loss. People with RP experience a gradual decline in their vision because photoreceptors degenerate. For more information on RP, visit our website at: https://lnkd.in/eEYBUKtt Video Description: Text reading “Here’s How Retinitis Pigmentosa Progression May Look For Some” on a blue background fades into an image of a child hanging on monkey bars. The center of the image becomes increasingly blurry and dark as labels reading “Mild Symptoms,” “Moderate Symptoms,” “Severe Symptoms” and “Profound Symptoms” appear. A final screen shows a green button reading “Click Here” above the words “To Learn More About Retinitis Pigmentosa.”

Spotlight on Retinitis Pigmentosa 👁️🗨️ Today, we’re highlighting how individuals with retinitis pigmentosa (RP) may experience the progression of their vision loss. People with RP experience a gradual decline in their vision because photoreceptors degenerate. For more information on RP, visit our website at: https://lnkd.in/em7rwEhv Video Description: Text reading “Here’s How Retinitis Pigmentosa Progression May Look For Some” on a blue background fades into an image of a child hanging on monkey bars. The center of the image becomes increasingly blurry and dark as labels reading “Mild Symptoms,” “Moderate Symptoms,” “Severe Symptoms” and “Profound Symptoms” appear. A final screen shows a green button reading “Click Here” above the words “To Learn More About Retinitis Pigmentosa.”

Understanding how zwitterionic polymers can lead to safer drugs and disease prevention. Researchers conducted a study to elucidate the mechanism of protein aggregation inhibition by sulfobetaine (SPB). In their study, the researchers also tried to understand the specific interactions that occur between hydrophobic components and proteins and their impact on protein aggregation. https://hubs.ly/Q02zRzfw0